Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Does it also protect the patient from cardiovascular complications?

Mechanism of Action Bromocriptine is unique in that it does not have a specific receptor that mediates its action on glucose and lipid metabolism. Rather, its effects are mediated via resetting of ...

In this GEN webinar, Dave Lahr, PhD, Senior Director of Bioinformatics at Foghorn Therapeutics, discusses chromatin ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...

Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...

In patients who transitioned from injected SRLs to once-daily oral PALSONIFY, mean insulin-like growth factor 1 (IGF-1) levels remained stable with IGF-1 (mean ± SE) of 0.93 ± 0.22 at OLE baseline and ...

In obese, insulin-resistant animals, treatment with the dopamine D2 receptor (D2R) agonist bromocriptine causes reversion to a lean, insulin-sensitive state. Kok and colleagues, therefore, studied ...

First subcutaneous, once-monthly octreotide for treatment of acromegaly For convenient self-administration with a pre-filled autoinjector pen LUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus ...

The Palsonify-treated subjects maintained control, with stable growth hormone levels, symptom scores, and pituitary tumour ...